Topic: pharma CEO

BMS CEO Giovanni Caforio's pay dipped slightly to $18.8 million last year, as his incentives were tied to the successful integration of Celgene.

Eli Lilly has refocused around new medicines and met many of its compensation targets in 2019, the company said in a proxy filing.

Albert Bourla's 2019 compensation jumped 82% over 2018's, but promotion to Pfizer's top job wasn't the only factor that boosted his pay.

The Zolgensma data integrity crisis wiped out the "building trust with society" part of Vas Narasimahan's annual bonus in 2019.

The major contribution to her pay growth comes from vesting of long-term awards, which totaled £5.08 million.

Amid a year of legal challenges over opioids and baby powder, Johnson & Johnson CEO Alex Gorsky nabbed a more than $5 million pay bump in 2019.

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune from.

New FibroGen CEO and former Eli Lilly vet, Enrique Conterno, cleared some existing investor doubts about roxadustat's potential.

AMAG Pharmaceuticals is saying goodbye to its CEO and two drugs after a strategic review, but are the moves too late to save the sinking ship?

Ian Read is taking on an operating executive job at Carlyle, just as Robert Essner became a senior adviser at the PE firm after retiring from Wyeth.